Mimivax, Llc

Description

• MimiVax's lead agent, SurVaxM, has recently completed its first-in-man clinical trial with strongly encouraging results. A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas. A phase I study in multiple myeloma, Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy is scheduled to open in March 2015. The phase II study in malignant glioma, Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma is being prepared for opening as a multicenter clinical trial to open in 2015. MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
• 

  Headquarters:Elm And Carlton St , Buffalo, New York, United States

  More
• 

  Phone Number: +1 716-630-8200

• 

  Website: https://www.mimivax.com

• 

  Employees:2

• 

  Revenue:$0 - 1M

• 

  Legal Name:Mimivax, Llc

• Mimivax, Llc's Social Media

  
• Is this data correct?

• |  NAICS Code: 621399  |

  Show More